The A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches

by Cheong, S.L., Federico, S., Venkatesan, G., Mandel, A.L., Shao, Y.-M., Moro, S., Spalluto, G., Pastorin, G.
Published 2014

Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo- pyrimidines as potent human A3 adenosine receptor antagonists

by Cheong, S.L., Federico, S., Venkatesan, G., Paira, P., Shao, Y.-M., Spalluto, G., Yap, C.W., Pastorin, G.
Published 2014

Aortic pulse wave velocity, central pulse pressure, augmentation index and chronic kidney disease progression in individuals with type 2 diabetes: A 3- year prospective study

by Liu, J.-J., Liu, S., Lee, J., Gurung, R.L., Yiamunaa, M., Ang, K., Shao, Y.M., Choo, R.W.M., Tavintharan, S., Tang, W.E., Sum, C.F., Lim, S.C.
Published 2021

Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson’s disease treatment

by Shao Y.-M., Ma X., Paira P., Tan A., Herr D.R., Lim K.L., Ng C.H., Venkatesan G., Klotz K.-N., Federico S., Spalluto G., Cheong S.L., Chen Y.Z., Pastorin G.
Published 2018